ERBB2 and fibrosarcoma: These clinical trials are currently investigating inhibitors of BRAF, human epidermal growth factor receptor-2 (HER2), and Pi3K/AKT/mTOR or rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase kinase (MEK) pathways on mutated tumors [9].